191 results about "Renal function" patented technology

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and / or P-gp only inhibitors.

The invention provides a multi-channel one-core multi-detection integrated detection method, which is applied to the technical field of in-vitro diagnosis and comprises the following steps: acquiring time sequence original signals of blood routine, liver function and kidney function channels; obtaining a baseline stable primary signal through cross-channel baseline trend coupling and adaptive correction; adopting a machine learning model to identify interference components and performing component offset to obtain a decoupling signal; mapping the decoupling signal into a physiological parameter value and carrying out rationality test; when the low credible parameter exists, a rechecking mechanism is triggered; performing weighted fusion on the basis of the rationality test result and the recheck signal to obtain a comprehensive parameter set; and finally generating a comprehensive detection report containing the credibility score. Cooperative processing and fusion analysis of multi-channel detection signals are realized, and the accuracy and reliability of a detection result are remarkably improved through interference identification and a dynamic recheck mechanism.

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and / or P-gp only inhibitors.

The invention relates to a nephrotic patient health management method and system based on a neural network prediction model, and the method comprises the steps: obtaining the multi-dimensional health data of a target nephrotic patient at each stage, constructing a time sequence feature matrix to extract the change trend of the whole course of disease, and dividing the course of disease into a disease alleviation stage and a disease deterioration stage; analyzing the health data of the two stages to obtain an improvement factor and a deterioration factor; outputting a renal function state prediction result by using a neural network prediction model fusing an attention mechanism and a knowledge graph, and generating an initial health management scheme by combining the result, a preset health management rule base and patient preferences; and optimizing the initial scheme based on the improvement factor, the deterioration factor and a reinforcement learning algorithm to obtain an optimized health management scheme. Complete-cycle closed-loop management of data acquisition, trend analysis, factor identification, prediction and early warning, scheme generation and dynamic optimization of nephropathy patients is realized, and the accuracy and individuation level of nephropathy health management are improved.

The invention relates to an intelligent decision-making system for nutrition metabolism collaborative management of elderly chronic disease patients, in particular to the field of nutrition metabolism collaborative management of elderly chronic disease, which is characterized in that drug molecule characteristics and nutrient metabolism paths are dynamically integrated through a multi-modal knowledge graph, and a cross-domain associated three-dimensional knowledge network is constructed; based on a reinforcement learning real-time optimization rule confidence threshold value, the early warning sensitivity is adaptively adjusted according to the degree that the metabolic index of the patient deviates from the safety interval; the streaming conflict detection engine accurately identifies the potential risk of asynchronously input medication and diet data, and triggers graded early warning through space-time alignment and sub-graph matching; the closed-loop evolution mechanism fuses patient compliance feedback and blood potassium change trend, drives the taboo rule base to continuously and autonomously evolve under the constraint of renal function layering, and realizes personalized risk prevention and control and metabolic state collaborative optimization.

The invention relates to the technical field of medical data processing, and discloses a non-invasive hemodynamic assessment system for coronary artery stenosis degree, comprising an image acquisition module used for acquiring a coronary artery computed tomography angiography image of a patient; the physiological signal acquisition module is used for synchronously acquiring physiological signals of a patient, and the physiological signals comprise electrocardiosignals and non-invasive arterial blood pressure signals; and the data processing module is used for preprocessing and segmenting the coronary artery computed tomography angiography image. Electrocardiogram and non-invasive arterial blood pressure signals are collected through the sensor, risks and complications caused by invasive examination of traditional coronary artery radiography are avoided, the problem that patients unsuitable for invasive examination such as contrast agent allergy and renal insufficiency are difficult to evaluate is solved, the pain of the patients is relieved, and the acceptability of the patients is improved.

The invention relates to application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of a medicine for resisting cholestatic liver diseases, and belongs to the technical field of medicinal chemistry. The 1, 2, 3, 4, 6-O-pentagalloylglucose provided by the invention can be used for promoting bile acid excretion by reducing WDR6 protein expression. In-vivo and in-vitro experiments prove that the 1, 2, 3, 4, 6-O-pentagalloylglucose can be used for remarkably relieving the symptom of the cholestatic liver disease. In addition, the 1, 2, 3, 4, 6-O-pentagalloylglucose has no obvious toxic or side effect, and has no obvious influence on the liver function and the kidney function. The 1, 2, 3, 4, 6-O-pentagalloylglucose has a wide anti-cholestatic liver disease spectrum, and is suitable for various cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and the like.

The invention provides a quadruple plasma blood purification device and purification method. The quadruple plasma blood purification device comprises a primary plasma separator, a secondary plasma separator, a perfusion device and a dialyzer, the inlet of the primary plasma separator is connected with the artery of a patient; an inlet of the secondary plasma separator is connected with the primary plasma separator; an inlet of the perfusion device is connected with the secondary plasma separator; and the dialyzer is respectively connected with the perfusion device and the primary plasma separator. According to the technology, only one-time operation is needed for treatment for 6-12 hours, multiple operations are not needed, meanwhile, the core pathogenesis of hypertriglyceridemia, cytokine storm sepsis, internal environment disorder and renal insufficiency which cause pancreatitis is solved, the treatment time is saved to a great extent, the risk that the illness state develops to death is reduced, and the treatment cost is reduced. The clinical effective treatment rate is improved; in addition, only one set of equipment is needed, and the device has the advantages of low cost, simplicity and convenience in operation, low time, manpower and financial resource consumption, high treatment efficiency and the like.

The invention belongs to the technical field of medicine, and particularly relates to polygonatum polysaccharide, a preparation method and application, the structural formula of the polygonatum polysaccharide is as follows: m1 + m2 = 11, n = 4; the rhizoma polygonati polysaccharide can relieve OS, inhibit inflammatory response, break vicious circle generated and activated by inflammation-OS-TGF-beta1 and block excessive activation and downstream signals of a key fibrosis factor TGF-beta1, so that renal dysfunction and renal fibrosis induced by adenine are remarkably improved, and the rhizoma polygonati polysaccharide has a good treatment effect on renal injury.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting cat Cys-C protein and application. The monoclonal antibody combination provided by the invention comprises monoclonal antibodies 4D5 and 3F3, and amino acid sequences of complementary determining regions (CDR) of variable regions of a heavy chain and a light chain of the monoclonal antibodies 4D5 and 3F3 are respectively shown as SEQ ID NO.1 to SEQ ID NO.12. The antibody combination has high specificity and sensitivity, and can effectively recognize cat Cys-C recombinant protein and natural cat Cys-C protein. According to the double-antibody sandwich ELISA detection method constructed based on the antibody combination, positive signals can still be generated under the low concentration of 1ng / mL, no obvious cross reaction exists, and the detection accuracy is remarkably improved. The antibody combination can be used for preparing a detection kit, a test strip, an antibody chip and other tools, and is suitable for cat kidney function evaluation and early auxiliary diagnosis of kidney diseases.

A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

The present invention provides an objective non-invasive method for examining renal dysfunction in cats. This method for testing renal dysfunction is a method for testing renal dysfunction in cats, and comprises a step for measuring the level of one or more D-amino acids selected from the group consisting of D-tyrosine, D-methionine, D-tryptophan, D-ornithine, and D-histidine in urine of a subject.

To provide a jelly composition containing spherical adsorptive carbon for improving uremic symptoms and delaying initiation of dialysis of chronic renal failure patients, which has more improved medication compliance than existing therapeutic agents.SOLUTION: The jelly composition contains spherical adsorptive carbon as an active ingredient, a gelling agent, a thickener, and spherical adsorptive carbon containing distilled water.SELECTED DRAWING: Figure 2

Disclosed herein are pyridyl compounds. Also described are specific conjugated nicorandil compounds. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the pyridyl compounds are disclosed for the treatment of diseases or conditions related to kidney or kidney functions.

A computer implemented method for determining a dosage of rivaroxaban for administering to a patient, the method comprising: receiving patient data relating to a patient, wherein the patient data includes a kidney function metric; processing the patient data with a dosage calculator to determine the dosage of rivaroxaban for administering to the patient, wherein the dosage calculator is derived from a plasma level prediction model; and indicating the dosage.

This invention belongs to the field of pharmaceutical analysis, specifically relating to a method for constructing a fingerprint spectrum of Shenfushu granules. The method for constructing a fingerprint spectrum of Shenfushu granules provided by this invention features high accuracy, high stability, good repeatability, good specificity, and strong specificity. The fingerprint spectrum analysis method for Shenfushu granules, a traditional Chinese medicine preparation for treating chronic renal failure, established by this invention can not only qualitatively analyze and identify the seven chemical components contained in this preparation, but also simultaneously present the characteristic peaks of five traditional Chinese medicines in the prescription, achieving the goal of overall quality control of multiple medicinal ingredients.

The application discloses application of tomato saponin in preparation of a uric acid reducing composition and belongs to the technical field of biological medicine. The uric acid reducing composition comprises 80-240 parts of tomato saponin, 50-120 parts of momordica charantia saponin, 25-100 parts of fruit and vegetable extract, 10-20 parts of schizonepeta turczanovii extract, 10-20 parts of terminalia catappa leaf extract and 40-100 parts of soluble dietary mixture. Animal experiment verification shows that the composition can effectively reduce blood uric acid level and improve kidney function through the synergistic effect of multi-target points such as inhibition of uric acid synthesis, promotion of uric acid excretion, anti-inflammatory kidney protection and metabolic regulation, and a safe and efficient solution is provided for hyperuricemia.

The invention relates to the technical field of traditional Chinese medicines, and discloses an external traditional Chinese medicine formula for treating arthralgia with syndrome of cold-dampness obstruction, which comprises the following ingredients: 10g of cassia twig, 6g of dried ginger, 12g of lycopodium clavatum, 12g of herba lycopi, 10g of notopterygium root, 10g of radix angelicae pubescentis, 9g of loose knot, 9g of semen brassicae, 10g of rhizoma corydalis, 15g of caulis spatholobi and 10g of cortex acanthopanacis. According to the external traditional Chinese medicine formula for treating the cold-dampness arthralgia, through accurate compatibility of medicinal materials with effects of warming and dispelling cold and dampness, promoting blood circulation to remove meridian obstruction and strengthening tendons and bones, a synergistic treatment system of warming and dredging, eliminating dampness, dredging collaterals and protecting bones is formed, so that symptoms such as joint crymodynia, stiffness and the like can be quickly relieved, cold-dampness evil can be eliminated from the pathogenesis level, and qi and blood circulation of joints can be improved; by adopting a standard processing technology and an optimized preparation method, the transdermal efficiency is improved while the irritation of the medicinal materials is reduced, the medicine can directly reach the focus, the gastrointestinal tract side effect caused by oral administration is avoided, and the traditional Chinese medicine composition is particularly suitable for middle-aged and elderly people and cold-dampness blockage type arthralgia patients with poor liver and kidney functions and sensitive skin.

The invention discloses a preparation rich in polygonatum sibiricum polypeptide and application of the preparation in diabetes mellitus. The composition is prepared from rhizoma polygonati polypeptide, semeglutide, astaxanthin, an active agent and a ferroptosis mixture. Pharmacodynamic experiments show that in a diabetic mouse model, fasting blood glucose can be remarkably reduced, the serum insulin level can be increased, renal function indexes can be improved, and expression of NLRP3 inflammation pathway related proteins (NLRP3, Caspase-1 and IL-1beta) in pancreatic tissue can be remarkably inhibited. By integrating multiple mechanisms of blood glucose reduction, oxidation resistance, inflammation resistance, ferroptosis resistance and the like, multi-target collaborative intervention is realized, the pharmaceutical composition is remarkably superior to a single component in the aspects of blood glucose reduction, pancreas islet function protection and complication alleviation, and a new clinical strategy is provided for treatment of diabetes mellitus, especially type 1 diabetes mellitus.

The invention provides a natural plant feed additive for protecting livers and kidneys of livestock and poultry and a preparation method, and relates to the field of feed additives, the feed additive is prepared from centella asiatica, penthorum chinense pursh, felwort, phyllanthus urinaria, purpleflower holly fruit, isatis root, polyporus umbellatus, pericarpium arecae, uncaria, cyrtomium fortunei, talc, cortex acanthopanacis and cassia twig. Experimental data show that the feed additive can significantly inhibit the activities of ALT, AST and ALP in serum, reduce the level of TBIL, enhance the activities of SOD and GSH-Px, recover T-AOC and reduce the generation amount of MDA, so that the multi-dimensional liver protection function of laying hens with acute liver injury is realized; meanwhile, the feed additive can significantly improve the average daily gain of the fattening pigs, reduce the feed-gain ratio, reduce the activity of ALT and AST, increase the content of TP and ALB, and achieve a multi-target comprehensive physiological regulation effect; in addition, the difference between the serum BUN content and the serum Cr content of each group of fattening pigs has no statistical significance, it is proved that the fattening pigs have no risk of renal dysfunction, and a new solution is provided for developing green and efficient functional feed additives.

The invention relates to the technical field of veterinary drugs, and particularly provides a veterinary carprofen injection and a preparation method thereof, the veterinary carprofen injection comprises carprofen, emodin, galuteolin, coumarin, Radix Astragali, wolfberry, Schisandra chinensis, resveratrol and other components. According to the veterinary carprofen injection, emodin and luteoloside are added for compound anti-inflammation, the dosage of carprofen is reduced, the kidney burden is relieved, meanwhile, drug resistance is not likely to be generated, radix astragali, fructus lycii and fructus schizandrae extracts are added for protecting the kidney, regulating immunity and avoiding renal function damage, and finally the effects of compound anti-inflammation and renal function damage avoiding are achieved.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

This invention discloses a class of pyrazolopyridine compounds linked by an aza-four-membered ring, or pharmaceutically acceptable salts thereof, and their applications. These compounds can serve as novel, highly selective PDE10A inhibitors for the treatment of peripheral tissue diseases, including: myocardial hypertrophy and cardiac dysfunction (heart failure), diabetes, hypertension, renal impairment and renal fibrosis, pulmonary inflammation and pulmonary fibrosis, immune dysregulation, and cancers (colon cancer, ovarian cancer, and lung cancer). Two strategies are employed to achieve high selectivity for PDE10A inhibition while simultaneously reducing the inhibitory effect on the central nervous system. First, molecular structure modification: structural optimization of the aza-four-membered ring-linked pyrazolopyridine compounds, such as increasing the ratio of N, O, and S atoms in the molecular structure to increase the polar surface area and reduce lipophilicity; and introducing hydrophilic groups to increase water solubility, thereby reducing the permeability of the compound to the blood-brain barrier (BBB). Second, targeted drug delivery to lung tissue via pharmaceutical formulation.

The invention discloses application of rosmarinic acid in preparation of a medicine or health food for preventing and treating hyperuricemia of a patient with renal insufficiency. The medicine for preventing and treating hyperuricemia of the patient with renal insufficiency is an XOD inhibitor or an ABCG2 gene expression promoter. The rosmarinic acid can significantly reduce the serum uric acid level of HUA mice induced by high purine diet, promote ABCG2-mediated intestinal uric acid excretion, and relieve HUA-induced intestinal inflammation and barrier injury by adjusting intestinal flora. The rosmarinic acid is safe and free of toxic and side effects, and has very important application prospects.

The invention relates to the technical field of biomedical detection, and particularly discloses a marker composition for diagnosing Alzheimer's disease and application of the marker composition. The marker composition comprises p-tau217 and GFAP, and can realize accurate screening of the early stage and the clinical stage of the Alzheimer's disease. The invention also provides a diagnostic reagent by using the marker composition, the reagent adopts a biotin-streptavidin amplification principle, and the detection accuracy of the biomarker can be obviously improved; meanwhile, a kit is designed based on the reagent, the partition pore plate design is adopted, and the cross contamination probability is reduced by arranging an isolation groove with a hydrophobic material. Besides, the invention further provides a system with diagnosis and correction functions, interference of hemolysis and / or renal insufficiency on Alzheimer's disease diagnosis can be eliminated, and the problem that an existing Alzheimer's disease diagnosis technology is prone to missed diagnosis and misdiagnosis is effectively solved.

The invention discloses an identification kit and an identification system for a pathogenic T cell subset of IgA nephropathy, and belongs to the technical field of nephropathy detection.According to the identification kit, the identification of the pathogenic T cell subset in peripheral blood of the IgA nephropathy is realized by adopting a fluorescent dye labeled antibody combination, and the antibody combination comprises a CD4 fluorescent antibody, a CD103 fluorescent antibody and an ITGB1 fluorescent antibody. The antibody combination designed by the invention can detect a pathogenic T cell subset in peripheral blood of IgA nephropathy, the T cell subset is in negative correlation with a renal function index eGFR, is in positive correlation with severity of E lesion and T lesion in IgA nephropathy kidney pathological injury oxford typing, and can be used as a significant predictive factor for reduction of eGFR and severity of E lesion and T lesion. The method has an important guiding value for real-time monitoring and prognosis prediction of the IgAN, and opens up a new view for clinical management of the IgAN.

The application provides application of Trapidil in preparation of a drug for preventing and / or treating doxorubicin-induced organ toxicity, and belongs to the technical field of biological medicines.The application discloses that Trapidil plays an organ protection role by activating a cAMP / PKA / CREB signal axis and driving two parallel downstream effect channels: on the one hand, up-regulating an NRF2-GPX3 positive feedback loop to inhibit doxorubicin-induced myocardial cell pyroptosis and glomerular podocyte pyroptosis; and on the other hand, activating an NRF2 / HO-1 channel to inhibit myocardial cell apoptosis and glomerular podocyte apoptosis.In-vivo and in-vitro experiments prove that Trapidil can improve doxorubicin-induced cardiac dysfunction and kidney function damage, reduce histopathological damage, reduce the level of oxidative stress, inhibit the pyroptosis and apoptosis of myocardial cells and glomerular podocytes, and does not affect the antitumor effect of doxorubicin.The application provides a new drug strategy for doxorubicin chemotherapy-induced multi-organ toxicity.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.